NQ Square TMS for Major Depressive Disorder: One Day, Three Sessions in Adults

Other illness

• Any medical conditions that would preclude the use of rTMS to treat depression.
• Any conditions that would prevent the ability to undergo MRI testing.
• History of epilepsy, seizure(s), or a seizure disorder as determined by the principal investigator based on a medical history obtained from the patient and/or others authorized to provide such history, combined with a brief screening instrument.
• Diagnosis of bipolar or psychotic disorder
• As determined by the Principal Investigator, subjects with cognitive impairment according to either the medical history obtained from the patient and/or a reliable secondary source, or the results of the Montreal Cognitive Assessment (MoCA) performed during screening.

Lab values

• Pregnancy as determined by serum/urine pregnancy test

Other

• Active substance abuse
• Considered to be at moderate-high risk of suicide according to the C-SSRS assessment (i.e., Answers YES to Question 3 and NO to Question 6; or answers YES to Question 4, 5, or 6)

• Males or females aged 22-85.
• Current diagnosis of major depressive disorder according to the criteria defined in the current Diagnosis and Statistical Manual of Mental Disorders (DSM-V) without psychotic features. The diagnosis of DSM-5 criteria-defined MDD will be made by a psychiatrist in light of a comprehensive psychiatric evaluation and other available clinical data.
• Drug-resistant MDD (lack of improvement on antidepressant medication in the current episode, despite adequate dose and duration and adherence to treatment).
• MADRS score \> 20 at baseline and immediately prior to the day of treatment.
• Agrees to adhere to the study treatment and follow-up schedule.
• Evidence of no change in AD medications or psychotherapy from 4 weeks prior to enrollment and participant's agreement not to request such changes through 2 weeks after study regimen treatment.
• Fluent in English.